Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Author(s) -
Steven Boonen,
JeanYves Reginster,
JeanMarc Kaufman,
Kurt Lippuner,
José Zanchetta,
Bente Langdahl,
René Rizzoli,
Stanley Lipschitz,
Hans Peter Dimai,
Richard Witvrouw,
Erik Fink Eriksen,
Kim Brixen,
Luis Augusto Tavares Russo,
Frank Claessens,
P. Papanastasiou,
Oscar Antúnez,
Guoqin Su,
Christina BucciRechtweg,
Josef Hruska,
Elodie Incera,
Dirk Vanderschueren,
Eric Orwoll
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1204061
Subject(s) - zoledronic acid , medicine , osteoporosis , hip fracture
Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom